NCT05201066

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

← 임상시험 허브

레지스트리 요약

진행 상태: 진행중(모집 종료) (ACTIVE_NOT_RECRUITING)
질환/조건: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
시험 유형: 중재 연구 (INTERVENTIONAL)
단계: Phase 2
목적: 치료
중재 유형: 약물
개입·치료: decitabine, spartalizumab, sabatolimab, azacitidine, venetoclax, INQOVI (oral decitabine)
Lead Sponsor: Novartis Pharmaceuticals (산업계)

캐시 시각: 2026-07-25 04:09:40

ClinicalTrials.gov에서 보기

요약

This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.

문의

이 시험 기반 리포트·메디컬라이팅이 필요하시면 문의해 주세요.

리포트 문의 메디컬라이팅 문의 맞춤 리서치 리포트